Equillium (EQ) Cash from Investing Activities (2018 - 2026)
Equillium (EQ) posted quarterly Cash from Investing Activities of -$3000.0 for Q1 2026, down 100.07% year-over-year from $4.5 million in Q1 2025, and up 90.62% quarter-over-quarter from -$32000.0 in Q4 2025.
Analysis
Equillium (EQ) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Cash from Investing Activities for 9 consecutive years, with -$3000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 100.07% year-over-year to -$3000.0; the TTM figure through Mar 2026 stood at -$35000.0 (down 100.17% YoY), while the FY2025 annual figure was $4.5 million, down 67.68% from the prior year.
- Cash from Investing Activities rose to -$3000.0 in Q1 2026 per EQ's latest filing, from -$32000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $15.0 million in Q3 2022 and bottomed at -$25.2 million in Q1 2023.
- Historically, Cash from Investing Activities has averaged $2.1 million across 5 years, with a median of $4.5 million in 2025.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 346.6% — and 2025, when it surged 258.81%.
- Equillium's Cash from Investing Activities stood at $7.0 million in 2022, then plunged by 179.76% to -$5.6 million in 2023, then jumped by 207.73% to $6.0 million in 2024, then tumbled by 100.53% to -$32000.0 in 2025, then surged by 90.62% to -$3000.0 in 2026.
- Business Quant data shows EQ's Cash from Investing Activities at -$3000.0 in Q1 2026, -$32000.0 in Q4 2025, and $4.5 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | -71,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -71,000.00 |
| Mar 31, 2026 | -3,000.00 |
| Dec 31, 2025 | -32,000.00 |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 6.00 Mn |
| Sep 30, 2024 | 12.00 Mn |
| Jun 30, 2024 | -1.35 Mn |
| Mar 31, 2024 | -2.83 Mn |
| Dec 31, 2023 | -5.57 Mn |
| Sep 30, 2023 | 10.99 Mn |
| Jun 30, 2023 | 15.00 Mn |
| Mar 31, 2023 | -25.18 Mn |
| Dec 31, 2022 | 6.98 Mn |
| Sep 30, 2022 | 15.00 Mn |
| Jun 30, 2022 | 8.69 Mn |
| Mar 31, 2022 | -11.99 Mn |
| Dec 31, 2021 | -16.89 Mn |
| Sep 30, 2021 | 10.47 Mn |
| Jun 30, 2021 | 28.97 Mn |
| Mar 31, 2021 | 4.86 Mn |